Kornimate/medical-research-clean huggingface dataset:
interest of salivary signature of endometriosis in the heathcare pathway of adolescent

Conditions: Endometriosis

Summary: adomiarn is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in obstetrics, gynecology and pediatrics departments in france and in belgium. the main objective is to confirm the interest of the in vitro diagnostic medical device (endotest®) in adolescents with suspected endometriosis. the study population is made up of females aged 10 to 19 years with formally diagnosed endometriosis or suspected endometriosis. the patients concerned by the study are managed without any change in the care pathway, no any change in the therapeutic indications, no any change in the diagnostic examinations (imaging or biology) required according to the context, which are carried out in accordance with the national guidelines. in this study, the management and follow-up of patients : * are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits, * are not modified in comparison with the usual follow-up, except for the performance of : * collection of saliva * completion of a self-questionnaire on symptom and quality-of-life.


Eligibility criteria:
inclusion criteria: * patient aged between 10 and 19 years, * patient over 18 or legal representatives of patient under 18 who has dated and signed the consent form, * patient with pelvic mri available and conduct within 12 months prior to inclusion, * patient from one of the 3 study populations: * a formal endometriosis diagnosed by clinical examination and imaging or * with prescription for coelioscopy because of a discrepancy between clinical and radiological findings or * a surgical indication for a pathology of the small pelvis other than endometriosis, in adolescents with suspected endometriosis faced with symptoms suggestive (dysmenorrhea, chronic or cyclic pelvic pain, urinary disorders cycle-dependent) * patient affiliated to the healthcare system. exclusion criteria: * known pregnancy in progress, * known infection with the human immunodeficiency virus (hiv), * personal history of cancer, * adolescent subject to a protective measure or placed adolescent, * adolescent or her legal representatives presenting important difficulties in reading french language, * patient or her legal representatives who have objected to the collection of her data, * patient participating in an interventional study with drug or medical device or in the exclusion period of an interventional study * patient who has participated or is participating in another study evaluating mirna in endometriosis.

Keywords: mirna rna machine learning algorithms adolescents
the paws-covid-19 (pediatric airway complications covid-19) registry

Conditions: Airway Management; COVID19

Summary: the covid-19 pandemic has disrupted anesthesia care all over the world. there remains very little data on current practice patterns and patient outcomes, particularly in anesthetized children. this is a prospective observational, multi-center study to investigate airway management related outcomes in children undergoing anesthesia during this pandemic. the investigators will compare the incidence of complications (particularly hypoxemia) in patients with covid-19 to those who are covid-19 negative during airway management. paws covid-19 registry https://is.gd/pedicovid19 registration link https://is.gd/researchrequest


Eligibility criteria:
inclusion criteria: * undergoing an inpatient or outpatient procedure under general anesthesia with or without regional analgesia * undergoing a diagnostic procedure under sedation or general anesthesia * undergoing an urgent or emergent procedure performed during and outside of the regular operating room schedule hours. exclusion criteria: * age \> 18 years. * children admitted to the operating room already intubated * children who require tracheal intubation for life-threatening conditions in the emergency department, intensive care, or hospital ward.

Keywords: covid19 pediatric intubation anesthesia
implications of medical low dose radiation exposure - breast cancer acute coronary events

Conditions: Breast Cancer Female; Acute Coronary Events; Cardiac Complications

Summary: medirad-brace aims to determine the relationship between 3d dose distributions in cardiac structures and the risk of acute coronary events (ace) and other cardiac complications in breast cancer (bc) patients to develop and externally validate multivariable normal tissue complication probability (ntcp) models to assess the risk of ace in individual patients based on cardiac dose metrics in the first 10 years after bc radiotherapy.


Eligibility criteria:
inclusion criteria: * female breast cancer patients; * treated with primary surgery for stage i-iii invasive adenocarcinoma of the breast or ductal carcinoma in situ (dcis); * age between 40-75 years at time of start rt; * who performance status 0-1; * planned for rt alone to the breast, the chest wall and/or the lymph node areas; * start of rt is between 01-01-2015 and 31-12-2013; * available planning ct scan and dose distribution; * adjuvant systemic treatment, including hormonal therapy or chemotherapy is allowed; * medical history of coronary artery disease and/or myocardial infarction is not an exclusion criterion; * written informed consent. exclusion criteria: * male breast cancer patients; * women with metastatic breast cancer (m1 disease); * any prior malignancy other than non-melanoma skin cancer; * previous thoracic or mediastinal radiation; * women treated with neoadjuvant chemotherapy.

Keywords: breast cancer radiotherapy cardiac complications acute coronary events ntcp model
comparing constraint-induced therapy and occupation-based intervention for optimal stroke recovery

Conditions: Stroke; Cerebrovascular Accident

Summary: this pilot study was designed to compare the effects of modified constraint-induced therapy and occupation-based intervention to increase functional motor recovery in stroke

the purpose of this study is to investigate change in motor performance and the extent of neuroplastic change associated with both occupation-based intervention and modified constraint-induced therapy (m-cit) in the recovery of upper extremity motor function following a stroke. transcranial magnetic imaging (tms) will be used to compare the difference in the brain reorganization of each client before and after the intervention to identify which technique is more effective in changing brain function. central hypothesis: stroke subjects with motor deficit receiving occupation-based interventions will demonstrate improved motor function greater to that of the subjects receiving m-cit interventions. sixteen participants with chronic stroke will be recruited for the study over the age 21. participants will be randomly assigned to one of the two therapy groups and will receive 55 minutes of therapy 2 times per week for 4 weeks for a total of 8 sessions.

Eligibility criteria:
inclusion criteria: * 21 years of age and older * at least 12 months from stroke * mild-to-severe upper extremity motor deficit * single ischemic or hemorrhagic stroke exclusion criteria: * history of head injury with loss of consciousness * seizures * severe alcohol or drug abuse * psychiatric illness interfering with participation in the study including uncontrolled depression * cognitive deficits severe enough to preclude informed consent * ferromagnetic material near the brain * individuals that could be pregnant * cardiac or neural pacemakers * if currently receiving occupational therapy services

Keywords: motor recovery human occupation-based practice motor training transcranial magnetic stimulation
post stroke psychological distress

Conditions: Stroke

Summary: neuro-psychological, cognitive and biochemical assessment matched with mr-imaging in acute and chronic poststroke conditions.

the study design relates to affective symptomatology, particularly poststroke depression and posttraumatic stress symptoms as well as to cognitive decline due to stress-related hypercortisolemia in the early phase after stroke. extended mri studies including a functional connectivity (fc-mri) paradigm have been incorporated to study on subacute midbrain neurodegeneration as a possible morphological correlate of functional and clinical findings.

Eligibility criteria:
inclusion criteria: * stroke in mca/acha territory of striato-capsular (at least 125mm³) or non-striatal (10-100cm³) involvement * mr-imaging can be conducted 24-48 hours of onset * preserved communication skills exclusion criteria: * patients with psychiatric conditions or medication in the last 4 weeks * severe medical conditions * limited prognosis

Keywords: stroke
analgesic efficacy of intravenous hyoscine-n-butylbromide (hnb) in abdominal colic associated with acute gastroenteritis

Conditions: Abdominal Cramps

Summary: this study aims to assess the analgesic efficacy and safety of intravenous 20 mg hyoscine-n-butylbromide versus placebo for the treatment of abdominal colic associated with acute gastroenteritis in the emergency department.

acute gastroenteritis is a frequent cause of emergency department (ed) presentation. mainstays of ed treatment are rehydration and antiemetics when needed. since crampy abdominal pain accompanies (diarrhea) acute gastroenteritis in 67-90% of patients, emergency physicians may have to deal with spasmodic colics in these patients. hyoscine-n-butylbromide (hnb), is an anticholinergic agent which has been in use as an antispasmodic agent for sixty years all over the world. it has been studied and revealed various efficacy for several conditions (e.g; biliary colic, renal colic, endoscopic interventions, radiologic interventions, during labor, nonspecific abdominal pain and irritable bowel syndrome). hnb is commonly used for symptomatic relief of abdominal cramps associated with acute gastroenteritis in the eds, whereas the literature lacks evidence regarding its efficacy and safety for this condition. the aim of this study is to assess the analgesic efficacy and safety of intravenous 20 mg hyoscine-n-butylbromide versus placebo in patients with abdominal colic associated with acute gastroenteritis in the emergency department.

Eligibility criteria:
inclusion criteria: * adult patients * presenting to the emergency department with abdominal cramps associated with acute gastroenteritis * the pain intensity score upon screening is at least 20 mm on visual analog scale * patients who agree to participate and sign the informed consent exclusion criteria: * patients younger than 18 years * pain of \> 7 days * use of any analgesic within 6 hours of ed presentation * concomitant medication with spasmolytics, anticholinergics, drugs affecting gastrointestinal motility such as metoclopramide, loperamide, opioid analgesics * patients who were administered dopamine antagonists before screening * documented or self-reported hypersensitivity to hyoscine-n-butylbromide * confirmed or suspected pregnancy * breastfeeding * glaucoma * myasthenia gravis * benign prostatic hyperplasia or urinary obstruction * any suspected other cause of acute abdominal pain * peritonism * mechanical stenosis of the gastrointestinal tract, paralytic ileus, megacolon * previous intestinal resection * history of inflammatory bowel disease * tachyarrhythmia * severe dehydration requiring fluid resuscitation immediately * unable to consent * refused to participate
effects of active release technique and instrument assisted soft tissue mobilization in patients with migraine

Conditions: Migraine Disorders

Summary: rationale of this research is to evaluate the outcome of active release technique and instrument assisted soft tissue mobilization on trigger points in subjects with migraine. the significance of this study is to identify which technique is superior in alleviating the symptoms of migraine. this study will help gather evidence on the practice of incorporating trigger point therapy in the treatment of migraine.

migraine is a neurological condition that typically causes painful headache attacks lasting from four to 72 hours that occur with additional symptoms, such as sensitivity to light, sound, smell, or touch. migraines occur most frequently in the morning, especially upon waking. migraines can be triggered by stress or hormones. migraine attacks are debilitating and can hinder the day to day activities and productivity of the patient. the purpose of the study was to evaluate the effects of active release technique and instrument assisted soft tissue mobilization on trigger points. it was a randomized, controlled trial, conducted among migraine patients. sample size was 54 by using epitool software. participants were randomly assigned to the intervention or control group after a baseline assessment with a lottery ticket and an opaque envelope.all participants in both groups were evaluated on baseline and post-intervention.

Eligibility criteria:
inclusion criteria: both male and female 18-30 years trigger points in trapezius , sternocleidomastoid and sub-occipitals (identified using travel and simmons criteria) migraine without aura subjects were cognitively capable and competent to follow the instructions exclusion criteria: dysfunctions in the temporomandibular joint. participant with a history of basilar migraine or hemiplegic migraine fracture of cervical spine currently on medication for migraine

Keywords: trigger points, active release technique, iatsm
kt(kt corporation)-snubh(seoul national university bundang hospital) u-health cooperative research

Conditions: Pressure Ulcer

Summary: the purpose of this study is to analyse utility and compatibility of u-health solution service based on mobile for chronic wound management.

in this study, 'the management of pressure ulcer' defined as procedures comprising wound assessment, wound dressing and infection control, visually evaluated the outcomes of 'the management of pressure ulcer' through the tele-consultation. this study designed to draw service targets based on utility and compatibility of u-health solution service and to analyse whether health providers use u-health solution service.

Eligibility criteria:
inclusion criteria: * subject who has pressure ulcer or health care provider for wound management exclusion criteria: * subject who have osteomyelitis * subject who have suppuration * subject who participated in other clinical trial within 30 days from screening date

Keywords: u-health chronic wound management pressure ulcer
extended follow-up of participants in preventive hiv vaccine studies in uganda

Conditions: HIV Infections

Summary: two previous studies of an hiv preventive vaccine, the step study and the phambili study, were halted because people who received the vaccine were more likely to become infected with hiv. why this vaccine failed is still being researched, but one reason may be related to the recombinant adenovirus type 5 (rad5) virus vector used in the vaccine. two trials of another hiv preventive vaccine that used a rad5 virus vector were conducted in uganda. this study will obtain follow-up safety information on participants in those trials.

two previous trials of an hiv preventive vaccine, referred to as the mrk rad5 vaccine, were halted because people receiving the vaccine were at greater risk of hiv infection. the mrk rad5 vaccine delivered parts of hiv inside a recombinant ad5 (rad5) virus vector, which is a modified version of a common virus that does not usually cause serious disease. analyses of these trials found that the increased risk of hiv infection was seen only in male participants who already had detectable antibodies to adenovirus type 5 (ad5). a different hiv preventive vaccine developed by the vaccine research center (vrc) at the u.s. national institutes of health (nih) also uses a rad5 virus vector. although this vaccine, referred to as vrc ad5, uses a rad5 virus vector, it is structured and delivered differently than the mrk rad5 vaccine. in two trials in uganda it has shown no serious side effects. this study will perform safety follow-ups on participants in these two trials, rv 156a/wrair 1078a and rv 172/wrair 1218. participants who received either the vaccine or the placebo will be recruited in order to compare health and hiv status. participants in this study will complete eight clinic visits over 1 year and 2 weeks. four visits will be completed at baseline and after 4, 8, and 12 months. during these visits, participants will be checked for health changes and complete a blood draw. as part of the blood tests performed, participants will be tested for hiv. every 2 weeks after the four visits mentioned (on days 14, 134, 254, and 374), participants will return to the clinic to receive the results of their hiv tests. on all eight visits, participants will also receive hiv risk reduction counseling.

Eligibility criteria:
inclusion criteria: * participated in either of the following studies: (1) rv 156a/wrair 1078a, or (2) rv 172/wrair 1218 * able to provide informed consent exclusion criteria: * incapacitating illness precluding clinic visits

Keywords: hiv prevention vaccine recombinant adenovirus-5 hiv preventative vaccine
study of suitable schedule of docetaxel,anthracycline and cyclophosphamide in adjuvant therapy of beast cancer

Conditions: Breast Neoplasms; Adjuvant; Chemotherapy

Summary: anthracycline based regimens followed by a taxane (calgb-9344 trial and nsabp-b28) or reversed (md anderson adjuvant trial) has already accepted as adjuvant therapy for node positive breast cancer. also in this group of patients, data from bcirg-001 trial had shown that six cycles of adjuvant tac (docetaxel, doxorubicin and cyclophosphamide) is superior to standard fac (5-fu, doxorubicin and cyclophosphamide ) combination in terms of both disease free and overall survival, while associated with a higher rate of febrile neutropenia. then question arose whether it is better to use docetaxel and anthracycline in combination or sequence.

in this national wide study, women with node positive operable breast cancer are eligible for inclusion.patients were designed to randomize to six cycles of adjuvant tac (taxotere® 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2), and four cycles of t(100mg/m2), followed by 4 cycles of ac(doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2). prophylaxis with g-csf was allowed for two arms when febrile neutropenia occurred in the first cycle of the study treatment. the second endpoint of this study is disease free survival. the primary objective is to compare the disease free survival rate and safety profiles of the above mentioned two arms.

Eligibility criteria:
inclusion criteria: * pt1-3,pn1-3,m0, operable breast cancer * karnofsky \>=80 * pregnant test negative exclusion criteria: * prior chemotherapy with anthracyclines and / or taxanes, except for neoadjuvant therapy * prior breast radiation * bilateral breast cancer * in-operable breast cancer * other health condition which may be contraindications for chemotherapy * contraindications for dexamethasone

Keywords: breast-adjuvant breast-chemotherapy combination chemotherapy regimens
using implementation intentions to reduce cannabis use

Conditions: Cannabis Use

Summary: the study will recruit frequent users of cannabis (defined at least fortnightly use) and randomize them either to: (1) form implementation intentions by linking situations in which they are tempted to use cannabis with strategies to avoid using cannabis in those situations by using a volitional help sheet, or (2) to consider the situations in which they are tempted to use cannabis alongside possible strategies to avoid using it as presented in the volitional help sheet but not to form implementation intentions. the effects on self-reported cannabis use will be assessed 1 month post-intervention. predictors of cannabis reduction will also be examined.

design: this study will use questionnaires to assess participants cannabis habits (frequency and amount of use) and then employ planning strategies to help them quit. follow up questionnaires will be used to ascertain the success of planning on reduction in cannabis use. sample size: we plan to recruit a minimum of 60 participants in each condition (120 total) but aim to collect data from as many participants as possible. recruitment: to participate in this study a person must be over the age of 18 and a frequent user of cannabis. the study will be advertised online on social media platforms. procedure: potential participants will follow an online link to a briefing sheet that provides information about the study. the sheet will also inform participants that they do not have to complete the questionnaire and that they can withdraw from the study at any time without giving a reason. once they have read the briefing sheet and generated their personal identity code, as instructed, they will complete the questionnaire online. a month after the participants have completed the initial questionnaire they will receive a link to a follow-up questionnaire via email. email addresses will be stored separately to study data and will be destroyed once the follow up phase has completed and their involvement in the study ends. outcomes and analysis: the main purpose of this study is to explore the role of planning in encouraging people to reduce cannabis use. quantitative analysis will be conducted to assess the effects of planning on cannabis use reduction. the investigators expect to find that planning is effective in helping people reduce their use.

Eligibility criteria:
inclusion criteria: * frequent cannabis user (at least fortnightly) exclusion criteria: * younger than 18 years of age * infrequent / no cannabis use (less than fortnightly)

Keywords: cannabis risk reduction